Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements - Summary of Recognized Revenue (Details)

v3.19.1
Collaboration and License Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue $ 19,086 $ 7,836 $ 5,704 $ 5,793 $ 4,040 $ 17,499 $ 15,357 $ 14,845 $ 38,419 $ 51,741 $ 59,731
Collaboration Revenue                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue [1]                 32,387 51,741 59,731
Other Revenue                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue [1]                 6,032 0 0
Collaboration and License Agreements                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 38,419 51,741 59,731
Collaboration and License Agreements | Collaboration Revenue, Recognition of Up Front Payment | Celgene                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 6,567 16,694 27,730
Collaboration and License Agreements | Collaboration Revenue, Recognition of Up Front Payment | Merck                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 6,985    
Collaboration and License Agreements | Collaboration Revenue, Recognition of Up Front Payment | Merck KGaA, Darmstadt, Germany “EMD Serono”)                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 4,142 4,120 4,120
Collaboration and License Agreements | Collaboration Revenue, Research and Development Services | Celgene                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 119 660  
Collaboration and License Agreements | Collaboration Revenue, Research and Development Services | Merck                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 1,541    
Collaboration and License Agreements | Collaboration Revenue, Research and Development Services | Merck KGaA, Darmstadt, Germany “EMD Serono”)                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 3,033 3,015 1,610
Collaboration and License Agreements | Collaboration Revenue, Milestones and Contingent Payments | Celgene                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 10,000 27,252 26,271
Collaboration and License Agreements | Collaboration Revenue                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 32,387 51,741 59,731
Collaboration and License Agreements | Collaboration Revenue | Celgene                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 16,686 44,606 54,001
Collaboration and License Agreements | Collaboration Revenue | Merck                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 8,526    
Collaboration and License Agreements | Collaboration Revenue | Merck KGaA, Darmstadt, Germany “EMD Serono”)                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 7,175 $ 7,135 $ 5,730
Collaboration and License Agreements | Other Revenue                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 6,032    
Collaboration and License Agreements | Other Revenue | Celgene                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 4,501    
Collaboration and License Agreements | Other Revenue | SutroVax                      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]                      
Total revenue                 $ 1,531    
[1] Includes $5.0 million of collaboration revenue and $3.9 million of other revenue from Celgene as related party revenue. Celgene was a related party through September 30, 2018 as it held more than 10% of our common stock for the periods presented until the closing of our IPO.